<p>阿尔法泰克控股公司（NASDAQ:ATEC - 获取免费报告）在周一的午盘交易中上涨了 7.4%。该公司的股价最高达到 8.18 美元，最后交易价为 8.2290 美元。在交易中，共成交 1,988,757 股，较平均交易量 3,373,418 股下降了 41%。该股票之前的收盘价为 7.66 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师对该公司进行了评估。TD Cowen 将阿尔法泰克的目标价从 20.00 美元下调至 11.00 美元，并在 5 月 6 日的研究报告中对该股票给予了 “买入” 评级。HC Wainwright 在 5 月 7 日的研究报告中重申了 “买入” 评级，并对阿尔法泰克的股票设定了 24.00 美元的目标价。巴克莱在 5 月 7 日的研究报告中将阿尔法泰克的目标价从 27.00 美元下调至 24.00 美元，并对该公司给予了 “增持” 评级。富国银行将阿尔法泰克的目标价从 28.00 美元下调至 14.00 美元，并在 5 月 7 日的报告中对该公司给予了 “增持” 评级。最后，Wall Street Zen 在 1 月 31 日的研究报告中将阿尔法泰克的评级从 “持有” 上调至 “买入”。十位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 18.58 美元。</p>
<p><strong>阅读我们关于 ATEC 的最新报告</strong></p>
<h2>阿尔法泰克价格表现</h2>
<p>该公司的速动比率为 1.12，流动比率为 1.90，债务与股本比率为 40.35。该公司的市值为 12.5 亿美元，市盈率为-9.89，贝塔值为 0.96。该股票的 50 日移动平均价格为 10.76 美元，200 日移动平均价格为 15.50 美元。</p>
<p>阿尔法泰克（NASDAQ:ATEC - 获取免费报告）最后一次公布财报是在 5 月 5 日，医疗技术公司报告本季度每股收益（EPS）为-0.22 美元，低于分析师的共识预期（-0.01 美元）0.21 美元。该季度的营业收入为 1.9211 亿美元，而分析师预期为 1.9751 亿美元。阿尔法泰克的净利润率为-15.93%，股本回报率为-1,183.84%。该公司的季度收入同比增长了 13.6%。去年同期，该公司的每股收益为-0.35 美元。股票分析师预测阿尔法泰克控股公司在当前财年将发布-0.44 美元的每股收益。</p>
<h2>阿尔法泰克内部活动</h2>
<p>在其他新闻中，执行副总裁 Craig E. Hunsaker 在 3 月 9 日的交易中出售了 82,765 股公司的股票。股票以平均价格 12.45 美元出售，总交易额为 1,030,424.25 美元。交易完成后，该执行副总裁持有公司 1,726,209 股股票，价值 21,491,302.05 美元。此次交易使其持股减少了 4.58%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，公司的总法律顾问 Tyson Eliot Marshall 在 3 月 5 日的交易中出售了 88,835 股公司的股票。股票以平均价格 12.49 美元出售，总交易额为 1,109,549.15 美元。交易完成后，总法律顾问持有公司 559,459 股股票，价值约 6,987,642.91 美元。此次交易使其持股减少了 13.70%。该交易的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士已出售 629,189 股公司股票，价值 7,801,589 美元。公司内部人士持有该股票的 13.48%。</p>
<h2>阿尔法泰克的机构交易</h2>
<p>一些机构投资者最近对 ATEC 的持仓进行了调整。先锋集团在第三季度将其在阿尔法泰克的持股提高了 2.4%。先锋集团目前拥有 6,815,058 股医疗技术公司的股票，价值 99,091,000 美元，此前在上个季度购买了 158,295 股。Tudor Investment Corp ET AL 在第三季度将其在阿尔法泰克的持股增加了 608.4%。Tudor Investment Corp ET AL 目前拥有 900,491 股医疗技术公司的股票，价值 13,093,000 美元，此前在上个季度购买了 773,367 股。Lisanti Capital Growth LLC 在第三季度收购了阿尔法泰克的新股份，价值约为 3,305,000 美元。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度购买了阿尔法泰克的新股份，价值约为 3,691,000 美元。最后，阿伯丁集团在第四季度将其在阿尔法泰克的持仓提高了 29.7%。阿伯丁集团目前拥有 1,286,195 股医疗技术公司的股票，价值 27,062,000 美元，此前在上个季度购买了 294,792 股。66.35% 的股票由机构投资者和对冲基金持有。</p>
<h2>阿尔法泰克公司简介</h2>
<p>（获取免费报告）</p>
<p>阿尔法泰克控股公司（NASDAQ: ATEC）是一家医疗技术公司，专注于设计、开发和商业化用于外科矫正退行性脊柱疾病的产品。该公司的产品组合以椎间植入物、生物材料、固定装置和外科规划工具为中心，旨在改善脊柱融合手术中的患者结果。阿尔法泰克的旗舰产品包括可定制的椎间笼、骨移植材料和专门的器械，旨在用于微创和开放脊柱手术。</p>
<p>阿尔法泰克成立于 1985 年，最初名为阿尔法泰克脊柱公司，并于 2018 年更名为阿尔法泰克控股公司，已从单一产品组织发展为脊柱市场的多平台创新者。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Alphatec</li>
<li>为什么 Applied Optoelectronics 的股票可能接近转折点</li>
<li>从高收益到高增长：三只提升股息的股票</li>
<li>Everspin Technologies 会是下一个 AI 边缘突破吗？</li>
<li>5 只机器人股票值得关注，因为物理 AI 正在蓬勃发展</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 到 Alphatec 吗？</h2>
<p>在考虑 Alphatec 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alphatec 并不在名单上。</p>
<p>虽然 Alphatec 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿尔法泰克控股

标普健康医疗设备 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

美国医药设备 ETF - iShares

<p>阿尔法泰克控股（NASDAQ:ATEC）在交易中股价上涨了 7.4%，达到 8.2290 美元，尽管成交量下降了 41%。分析师们的看法不一，价格目标范围从 11.00 美元到 24.00 美元不等。该公司报告的季度收入为 1.9211 亿美元，但未能达到每股收益预期。内部交易活动中出现了大量股票出售，机构投资者也调整了在该公司的持仓</p>

<p>Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) shot up 7.4% during mid-day trading on Monday . The company traded as high as $8.18 and last traded at $8.2290. 1,988,757 shares traded hands during trading, a decline of 41% from the average session volume of 3,373,418 shares. The stock had previously closed at $7.66.</p>
<div class="lb-trans"><p>阿尔法泰克控股公司（NASDAQ:ATEC - 获取免费报告）在周一的午盘交易中上涨了 7.4%。该公司的股价最高达到 8.18 美元，最后交易价为 8.2290 美元。在交易中，共成交 1,988,757 股，较平均交易量 3,373,418 股下降了 41%。该股票之前的收盘价为 7.66 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have weighed in on the company. TD Cowen cut their price target on Alphatec from $20.00 to $11.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, May 6th. HC Wainwright restated a &#34;buy&#34; rating and issued a $24.00 target price on shares of Alphatec in a research note on Thursday, May 7th. Barclays reduced their price target on Alphatec from $27.00 to $24.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, May 7th. Wells Fargo &amp; Company decreased their price target on Alphatec from $28.00 to $14.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday, May 7th. Finally, Wall Street Zen upgraded Alphatec from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, January 31st. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $18.58.</p>
<div class="lb-trans"><p>几位股票研究分析师对该公司进行了评估。TD Cowen 将阿尔法泰克的目标价从 20.00 美元下调至 11.00 美元，并在 5 月 6 日的研究报告中对该股票给予了 “买入” 评级。HC Wainwright 在 5 月 7 日的研究报告中重申了 “买入” 评级，并对阿尔法泰克的股票设定了 24.00 美元的目标价。巴克莱在 5 月 7 日的研究报告中将阿尔法泰克的目标价从 27.00 美元下调至 24.00 美元，并对该公司给予了 “增持” 评级。富国银行将阿尔法泰克的目标价从 28.00 美元下调至 14.00 美元，并在 5 月 7 日的报告中对该公司给予了 “增持” 评级。最后，Wall Street Zen 在 1 月 31 日的研究报告中将阿尔法泰克的评级从 “持有” 上调至 “买入”。十位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 18.58 美元。</p>
</div><p><strong>Read Our Latest Report on ATEC</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ATEC 的最新报告</strong></p>
</div><h2>Alphatec Price Performance</h2>
<div class="lb-trans"><h2>阿尔法泰克价格表现</h2>
</div><p>The company has a quick ratio of 1.12, a current ratio of 1.90 and a debt-to-equity ratio of 40.35. The firm has a market capitalization of $1.25 billion, a PE ratio of -9.89 and a beta of 0.96. The stock has a 50-day moving average price of $10.76 and a 200 day moving average price of $15.50.</p>
<div class="lb-trans"><p>该公司的速动比率为 1.12，流动比率为 1.90，债务与股本比率为 40.35。该公司的市值为 12.5 亿美元，市盈率为-9.89，贝塔值为 0.96。该股票的 50 日移动平均价格为 10.76 美元，200 日移动平均价格为 15.50 美元。</p>
</div><p>Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.21). The business had revenue of $192.11 million for the quarter, compared to analysts' expectations of $197.51 million. Alphatec had a negative net margin of 15.93% and a negative return on equity of 1,183.84%. The company's quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.35) EPS. Equities analysts forecast that Alphatec Holdings, Inc. will post -0.44 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>阿尔法泰克（NASDAQ:ATEC - 获取免费报告）最后一次公布财报是在 5 月 5 日，医疗技术公司报告本季度每股收益（EPS）为-0.22 美元，低于分析师的共识预期（-0.01 美元）0.21 美元。该季度的营业收入为 1.9211 亿美元，而分析师预期为 1.9751 亿美元。阿尔法泰克的净利润率为-15.93%，股本回报率为-1,183.84%。该公司的季度收入同比增长了 13.6%。去年同期，该公司的每股收益为-0.35 美元。股票分析师预测阿尔法泰克控股公司在当前财年将发布-0.44 美元的每股收益。</p>
</div><h2>Insider Activity at Alphatec</h2>
<div class="lb-trans"><h2>阿尔法泰克内部活动</h2>
</div><p>In other news, EVP Craig E. Hunsaker sold 82,765 shares of the business's stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $12.45, for a total transaction of $1,030,424.25. Following the completion of the sale, the executive vice president owned 1,726,209 shares of the company's stock, valued at $21,491,302.05. The trade was a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, General Counsel Tyson Eliot Marshall sold 88,835 shares of the company's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the transaction, the general counsel owned 559,459 shares of the company's stock, valued at approximately $6,987,642.91. This trade represents a 13.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 629,189 shares of company stock worth $7,801,589 in the last ninety days. 13.48% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Craig E. Hunsaker 在 3 月 9 日的交易中出售了 82,765 股公司的股票。股票以平均价格 12.45 美元出售，总交易额为 1,030,424.25 美元。交易完成后，该执行副总裁持有公司 1,726,209 股股票，价值 21,491,302.05 美元。此次交易使其持股减少了 4.58%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，公司的总法律顾问 Tyson Eliot Marshall 在 3 月 5 日的交易中出售了 88,835 股公司的股票。股票以平均价格 12.49 美元出售，总交易额为 1,109,549.15 美元。交易完成后，总法律顾问持有公司 559,459 股股票，价值约 6,987,642.91 美元。此次交易使其持股减少了 13.70%。该交易的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士已出售 629,189 股公司股票，价值 7,801,589 美元。公司内部人士持有该股票的 13.48%。</p>
</div><h2>Institutional Trading of Alphatec</h2>
<div class="lb-trans"><h2>阿尔法泰克的机构交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in ATEC. Vanguard Group Inc. lifted its holdings in Alphatec by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company's stock valued at $99,091,000 after purchasing an additional 158,295 shares in the last quarter. Tudor Investment Corp ET AL grew its holdings in shares of Alphatec by 608.4% during the third quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company's stock worth $13,093,000 after buying an additional 773,367 shares in the last quarter. Lisanti Capital Growth LLC acquired a new stake in shares of Alphatec in the third quarter valued at about $3,305,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Alphatec in the fourth quarter worth about $3,691,000. Finally, Aberdeen Group plc boosted its position in Alphatec by 29.7% during the fourth quarter. Aberdeen Group plc now owns 1,286,195 shares of the medical technology company's stock worth $27,062,000 after acquiring an additional 294,792 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近对 ATEC 的持仓进行了调整。先锋集团在第三季度将其在阿尔法泰克的持股提高了 2.4%。先锋集团目前拥有 6,815,058 股医疗技术公司的股票，价值 99,091,000 美元，此前在上个季度购买了 158,295 股。Tudor Investment Corp ET AL 在第三季度将其在阿尔法泰克的持股增加了 608.4%。Tudor Investment Corp ET AL 目前拥有 900,491 股医疗技术公司的股票，价值 13,093,000 美元，此前在上个季度购买了 773,367 股。Lisanti Capital Growth LLC 在第三季度收购了阿尔法泰克的新股份，价值约为 3,305,000 美元。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度购买了阿尔法泰克的新股份，价值约为 3,691,000 美元。最后，阿伯丁集团在第四季度将其在阿尔法泰克的持仓提高了 29.7%。阿伯丁集团目前拥有 1,286,195 股医疗技术公司的股票，价值 27,062,000 美元，此前在上个季度购买了 294,792 股。66.35% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Alphatec Company Profile</h2>
<div class="lb-trans"><h2>阿尔法泰克公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.</p>
<div class="lb-trans"><p>阿尔法泰克控股公司（NASDAQ: ATEC）是一家医疗技术公司，专注于设计、开发和商业化用于外科矫正退行性脊柱疾病的产品。该公司的产品组合以椎间植入物、生物材料、固定装置和外科规划工具为中心，旨在改善脊柱融合手术中的患者结果。阿尔法泰克的旗舰产品包括可定制的椎间笼、骨移植材料和专门的器械，旨在用于微创和开放脊柱手术。</p>
</div><p>Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.</p>
<div class="lb-trans"><p>阿尔法泰克成立于 1985 年，最初名为阿尔法泰克脊柱公司，并于 2018 年更名为阿尔法泰克控股公司，已从单一产品组织发展为脊柱市场的多平台创新者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Alphatec</li>
<li>Why Applied Optoelectronics Stock May Be Near a Turning Point</li>
<li>From High-Yield to High-Growth: 3 Stocks Boosting Dividends</li>
<li>Is Everspin Technologies the Next AI Edge Breakout?</li>
<li>5 Robotics Stocks to Watch as Physical AI Builds Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Alphatec</li>
<li>为什么 Applied Optoelectronics 的股票可能接近转折点</li>
<li>从高收益到高增长：三只提升股息的股票</li>
<li>Everspin Technologies 会是下一个 AI 边缘突破吗？</li>
<li>5 只机器人股票值得关注，因为物理 AI 正在蓬勃发展</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Alphatec Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 到 Alphatec 吗？</h2>
</div><p>Before you consider Alphatec, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Alphatec 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alphatec 并不在名单上。</p>
</div><p>While Alphatec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alphatec 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿尔法泰克控股（NASDAQ:ATEC）股价上涨 7.4% - 这是原因